Aandeel Galapagos AEX:GLPG.NL, BE0003818359

quote:

Wallander schreef op 13 december 2016 19:36:

[...]

En met BSA begon het veelbelovend.

quote:

Chicken . Jazeker wel! schreef op 13 december 2016 19:48:

dat mens had onwijs veel aandacht nodig.

quote:

Chicken . Jazeker wel! schreef op 13 december 2016 19:52:

[...]
er is altijd nog de twitterfeed

twitter.com/BioStockAddict

quote:

Chicken . Jazeker wel! schreef op 13 december 2016 19:52:

[...]
er is altijd nog de twitterfeed

twitter.com/BioStockAddict

quote:

egeltjemetstekel schreef op 13 december 2016 19:52:

[...]is dat soms voor jou de reden geweest ons landje te verlaten?

quote:

pardon schreef op 13 december 2016 17:34:

Gilead dividend en bijna 2 $ hoger vandaag.

In March, the company shuttered a half dozen trials seeking to expand the use of its cancer drug Zydelig. Since then, Gilead Sciences has stopped development of GS-5745 for ulcetrative colitis and Crohn's disease, and reported disappointing results for its cardiovascular drug GS-6615. Recently, results for the NASH (a liver disease) drug GS-4997 failed to impress industry watchers, too.

Given Gilead Sciences' top line was 10% smaller in the third quarter than a year ago, the company could use a win. Unfortunately, that win isn't likely to be momelotinib.

Fails to outperform
Results from two momelotinib phase 3 trials were reported, and neither of them delivered data that's likely to reshape how doctors treat myelofibrosis patients.

In Gilead Sciences' Simplify-1 study, momelotinib was statistically non-inferior to Jakafi in reducing spleen volume, with 26.5% of momelotinib patients and 29% of Jakafi patients achieving at least a 35% reduction. However, non-inferiority was not achieved for the secondary endpoint of response rate in total symptom score.

In the Simplify-2 study, momelotinib failed to meet its primary endpoint in a study evaluating its superiority to best alternative therapy, which in most cases was Jakafi.

Gilead Sciences' chief scientific officer, Norbert Bischofberger, attempted to put a positive spin on the results by highlighting some improvements in anemia-related secondary endpoints, but Bischofberger's attempts add little confidence that momelotinib has any chance of displacing Jakafi in the indication. "The results from both the SIMPLIFY-1 and SIMPLIFY-2 studies indicate that momelotinib provides some treatment benefit, including benefit on anemia-related endpoints," said Bischofberger, adding, "We plan to discuss these results with regulatory authorities to determine the next steps."

Maintaining its lead
Incyte's twice-daily Jakafi won FDA approval for use in myelofibrosis patients in 2011 and notched an FDA green light in polycythemia vera -- another bone marrow disease -- in 2014. Sales of Jakafi have been building ever since.

In Q3, Jakafi's sales of $224 million were 39% higher than in the same quarter last year; and earlier this month, management said Jakafi's sales would be between $850 million and $855 million this year. In 2015, Jakafi's sales were $601 million. In the past year, the numbers of myelofibrosis patients and polycythemia vera patients taking Jakafi have increased by roughly 20% and 40%, respectively.

G

IMAGE SOURCE: INCYTE CORPORATION.

Given momelotinib's performance, it's unlikely Jakafi's position in the indication is in jeopardy, and that adds important clarity to Incyte's sales potential for 2017.

Eyes on the future
Gilead Sciences still has some promising candidates in development, including filgotinib, an autoimmune disease treatment that's in phase 3 studies. Pressure, however, is mounting for Gilead Sciences to deliver some R&D wins, or to deploy its massive cash stockpile to buy future growth. So far, Gilead Sciences' management has been coy about its acquisition plans, but it has indicated the company remains interested in expanding in oncology. Perhaps momelotinib's results mean that Incyte has become an attractive target. Regardless, it appears Jakafi's market share will remain intact, at least for now, and that's good news for Incyte investors.

quote:

keerputbever schreef op 13 december 2016 22:41:

Zal ik al een januaridraadje aanmaken of is dat wat vroeg ?

quote:

Gala-diner schreef op 13 december 2016 22:45:

[...]

Lijkt mij wat vroeg en er zijn betere posters die januari kunnen openen lijkt mij...

quote:

keerputbever schreef op 13 december 2016 22:48:

[...]

Zelfs meester Henk vond het verhaaltje van Kelewan niet zo goed.